The Role of Inducible NOS2 Gene Polymorphism in the Development of Essential Arterial Hypertension
- 4 Downloads
The risk of essential arterial hypertension was assessed in carriers of the NOS2 gene variants (rs1800482 (-954G>C), rs3730017 (C>T)). In subjects carrying C allele (rs1800482), the risk for essential arterial hypertension developing was higher by 1.7 times (OR=1.712, 95%CI 1.07-2.74), while the presence of T-allele (rs3730017) had a protective effect (OR=0.304, 95%CI 0.192-0.482). In patients with essential arterial hypertension, the presence of the C allele (rs1800482) was associated with a higher content of NO metabolites in the blood plasma. A positive correlation was found between the plasma content of nitrites and nitrates and the level of transcripts of VCAM1, ICAM1 genes in peripheral blood leukocytes. We found the influence of the C allele carriership on the expression VCAM1 and ICAM1 genes in patients with essential hypertension. It was hypothesized that this polymorphic site in the NOS2 gene can be involved in the development of endothelial dysfunction and essential arterial hypertension through modulation of NO level under condition of inflammation.
Key Wordsessential arterial hypertension NOS2 gene nitrogen oxide metabolites VCAM1 gene transcripts ICAM1 gene transcripts
Unable to display preview. Download preview PDF.
- 1.Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Sistemn. Gipertenzii. 2010;(3):5-26. Russian.Google Scholar
- 2.Metelskaya VA, Gumanova NG. Screening as a method for determining the serum level of nitric oxide metabolites. Klin. Lab. Diagnost. 2005;(6):15-18. Russian.Google Scholar
- 3.Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology. Moscow, 1998. Russian.Google Scholar
- 6.Kawaguchi Y, Tochimoto A, Hara M, Kawamoto M, Sugiura T, Katsumata Y, Okada J, Kondo H, Okubo M, Kamatani N. NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity. Arthritis Res. Ther. 2006;8(4). R104.CrossRefGoogle Scholar
- 8.Levesque MC, Hobbs MR, Anstey NM, Vaughn TN, Chancellor JA, Pole A, Perkins DJ, Misukonis MA, Chanock SJ, Granger DL, Weinberg JB. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production and disease severity in Tanzanian children with malaria. J. Infect. Dis. 1999;180(6):1994-2002.CrossRefGoogle Scholar
- 12.Pinto Lde F, Compri CM, Fornari JV, Bartchewsky W, Cintra DE, Trevisan M, Carvalho Pde O, Ribeiro ML, Velloso LA, Saad MJ, Pedrazzoli J Jr, Gambero A. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int. 2010;30(4):603-610.CrossRefGoogle Scholar